You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tyrosine kinase inhibitor, pharmacokinetics, therapeutic drug monitoring

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia

Not yet recruiting
  • Tyrosine Kinase Inhibitor
  • +2 more
    • Taipei, Taiwan
      National Taiwan University Hospital
    Feb 17, 2022

    Resistance to Tyrosine Kinase Inhibitor Osimertinib and

    Recruiting
    • Lung Cancer
    • Blood Samples
    • Lorient, France
    • +3 more
    Apr 26, 2022

    ALK-positive NSCLC in Sweden: Sequencing of ALK Tyrosine Kinase

    Completed
    Has Results
    • ALK-positive NSCLC
    • Sollentuna, Sweden
      Pfizer Innovations AB
    Mar 14, 2022

    Kinase Inhibitor Targeted Therapies

    Not yet recruiting
    • Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib
    • Measurement of drug concentrations
    • Rennes, France
    • +2 more
    Nov 7, 2022

    Melanoma (Skin) Trial in Dijon, Thionville, Vandœuvre-lès-Nancy (Blood sampling)

    Active, not recruiting
    • Melanoma (Skin)
    • Blood sampling
    • Dijon, France
    • +3 more
    Mar 29, 2022

    Stage II Renal Cell Cancer, Stage III Renal Cell Cancer Trial (tivozanib, therapeutic conventional surgery)

    Withdrawn
    • Stage II Renal Cell Cancer
    • Stage III Renal Cell Cancer
    • (no location specified)
    Aug 11, 2022

    Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable Trial in San Antonio (OTX-2002, Tyrosine kinase

    Not yet recruiting
    • Hepatocellular Carcinoma
    • +6 more
    • San Antonio, Texas
      Next Oncology
    Aug 9, 2022

    Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Brisbane (D-4517.2)

    Completed
    • Neovascular Age-related Macular Degeneration
    • Diabetic Macular Edema
    • Brisbane, Queensland, Australia
      Nucleus Network (Brisbane)
    Sep 19, 2022

    NSCLC Stage IV Trial in Taipei (therapeutic thoracic surgery, Afatinib)

    Recruiting
    • NSCLC Stage IV
    • Taipei, Taiwan
    • +1 more
    Mar 8, 2022

    Autism Spectrum Disorder Trial in Rotterdam (Therapeutic Drug Monitoring, Risperidone plasma level)

    Recruiting
    • Autism Spectrum Disorder
    • Therapeutic Drug Monitoring
    • Risperidone plasma level
    • Rotterdam, Netherlands
      Erasmus Medical Center
    Nov 23, 2021

    NSCLC Trial in Seoul (BBT-176, Cetuximab)

    Recruiting
    • NSCLC
    • Seongnam-si, Gyeonggi-do, Korea, Republic of
    • +3 more
    Jan 6, 2023

    Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL, Part3: Untreated CLL Trial in Japan (Acalabrutinib, Obinutuzumab)

    Active, not recruiting
    • Part1: Advanced B-cell Malignancies
    • +2 more
    • Chiba-shi, Japan
    • +13 more
    Jan 31, 2022

    Chronic Myeloid Leukemia Trial in Worldwide (Omacetaxine mepesuccinate)

    Terminated
    Has Results
    • Chronic Myeloid Leukemia
    • Omacetaxine mepesuccinate
    • Jacksonville, Florida
    • +9 more
    Nov 6, 2021

    Non-Hodgkin's B-cell Lymphoma Trial in Nanjing (DZD9008)

    Suspended
    • Non-Hodgkin's B-cell Lymphoma
    • Nanjing, China
    • +1 more
    Jun 10, 2021

    Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in San Antonio (D-4517.2)

    Recruiting
    • Neovascular Age-related Macular Degeneration
    • Diabetic Macular Edema
    • Los Angeles, California
    • +11 more
    Jan 11, 2023

    Atrial Fibrillation Trial in Caen (Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®))

    Not yet recruiting
    • Atrial Fibrillation
    • Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)
    • Caen, Normandie, France
      Caen University Hospital, Department of Pharmacology
    Sep 6, 2023

    Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • Chronic Lymphocytic Leukemia
    • East Melbourne, Victoria, Australia
    • +7 more
    Jan 20, 2023

    Primary Membranous Nephropathy Trial (EVER001)

    Not yet recruiting
    • Primary Membranous Nephropathy
    • (no location specified)
    Mar 23, 2023

    CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

    Recruiting
    • CML
    • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
    • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
      FUNDALEU
    Jun 29, 2023

    Sarcoma, Malignant Peripheral Nerve Sheath Tumors Trial in United States (PLX3397, Sirolimus)

    Recruiting
    • Sarcoma
    • Malignant Peripheral Nerve Sheath Tumors
    • Iowa City, Iowa
    • +4 more
    Aug 26, 2021

    Solid Tumors Harboring NTRK Fusion Trial in Mannheim (Selitrectinib (BAY2731954))

    Completed
    • Solid Tumors Harboring NTRK Fusion
    • Selitrectinib (BAY2731954)
    • Mannheim, Baden-Württemberg, Germany
      CRS Clinical-Research-Services Mannheim GmbH
    Dec 28, 2020

    Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in Worldwide (procedure, other, drug)

    Recruiting
    • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • Biospecimen Collection
    • +4 more
    • Birmingham, Alabama
    • +170 more
    Jan 30, 2023

    Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

    Not yet recruiting
    • Lung Cancer
    • Non Small Cell Lung Cancer
    • Amivantamab 1050mg
    • +2 more
    • Aurora, Colorado
    • +2 more
    Apr 25, 2023

    Multiple Myeloma, DLBCL, Glioblastoma Multiforme Trial in Worldwide (CC-223)

    Completed
    Has Results
    • Multiple Myeloma
    • +6 more
    • Los Angeles, California
    • +15 more
    Dec 9, 2022

    Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)

    Recruiting
    • Acute Lymphoblastic Leukemia
    • Ann Arbor, Michigan
      University of Michigan Rogel Cancer Center
    Nov 28, 2022